CN115515645A - 治疗骨关节炎的方法 - Google Patents

治疗骨关节炎的方法 Download PDF

Info

Publication number
CN115515645A
CN115515645A CN202080095849.5A CN202080095849A CN115515645A CN 115515645 A CN115515645 A CN 115515645A CN 202080095849 A CN202080095849 A CN 202080095849A CN 115515645 A CN115515645 A CN 115515645A
Authority
CN
China
Prior art keywords
protein
vector
active fragment
nucleic acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095849.5A
Other languages
English (en)
Chinese (zh)
Inventor
P·M·雷东多
I·吉伦-吉伦
J·C·伊兹皮苏亚贝尔蒙特
N·戴维森
G·M·丘奇
P·吉伦加西亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Harvard University
Original Assignee
Salk Institute for Biological Studies
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies, Harvard University filed Critical Salk Institute for Biological Studies
Publication of CN115515645A publication Critical patent/CN115515645A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN202080095849.5A 2019-12-05 2020-12-04 治疗骨关节炎的方法 Pending CN115515645A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944027P 2019-12-05 2019-12-05
US62/944,027 2019-12-05
PCT/US2020/063319 WO2021113642A1 (en) 2019-12-05 2020-12-04 Methods for treating osteoarthritis

Publications (1)

Publication Number Publication Date
CN115515645A true CN115515645A (zh) 2022-12-23

Family

ID=76222269

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080095849.5A Pending CN115515645A (zh) 2019-12-05 2020-12-04 治疗骨关节炎的方法

Country Status (8)

Country Link
US (1) US20230024183A1 (https=)
EP (1) EP4069313A4 (https=)
JP (2) JP7701359B2 (https=)
KR (1) KR20220119056A (https=)
CN (1) CN115515645A (https=)
AU (1) AU2020398637A1 (https=)
CA (1) CA3160033A1 (https=)
WO (1) WO2021113642A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250000512A (ko) 2023-06-27 2025-01-03 동신대학교산학협력단 요오드아세트산 나트륨 유도 골관절염에 양릉천과 현종 혈위를 자극하는 침습형 레이저침을 이용한 치료 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258588A1 (en) * 1998-04-03 2006-11-16 Novartis Vaccines And Diagnostics, Inc. Compositions and methods for treating articular cartilage disorders
CN102015760A (zh) * 2008-01-28 2011-04-13 诺瓦提斯公司 使用klotho-fgf融合多肽的方法和组合物
CN109844124A (zh) * 2016-05-20 2019-06-04 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
CN109996555A (zh) * 2016-11-22 2019-07-09 克洛索治疗有限公司 新颖重组klotho蛋白及其组合物和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2330939A1 (en) * 1998-06-16 1999-12-23 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
WO2017210607A1 (en) * 2016-06-02 2017-12-07 Klotho Therapeutics, Inc. Therapeutic recombinant klotho proteins and compositions and methods involving the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258588A1 (en) * 1998-04-03 2006-11-16 Novartis Vaccines And Diagnostics, Inc. Compositions and methods for treating articular cartilage disorders
CN102015760A (zh) * 2008-01-28 2011-04-13 诺瓦提斯公司 使用klotho-fgf融合多肽的方法和组合物
CN109844124A (zh) * 2016-05-20 2019-06-04 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
CN109996555A (zh) * 2016-11-22 2019-07-09 克洛索治疗有限公司 新颖重组klotho蛋白及其组合物和方法

Also Published As

Publication number Publication date
KR20220119056A (ko) 2022-08-26
JP2023504201A (ja) 2023-02-01
US20230024183A1 (en) 2023-01-26
AU2020398637A1 (en) 2022-06-30
EP4069313A4 (en) 2024-02-28
EP4069313A1 (en) 2022-10-12
JP2025126223A (ja) 2025-08-28
CA3160033A1 (en) 2021-06-10
JP7701359B2 (ja) 2025-07-01
WO2021113642A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
JP2025148444A (ja) 未成熟終止コドン媒介障害を処置するための方法および組成物
US12023386B2 (en) Composition for treatment of Crigler-Najjar syndrome
CN109121421B (zh) 用于治疗家族性高胆固醇血症的基因疗法
AU2018261003A1 (en) Compositions and methods of treating Huntington's Disease
JP2018504929A (ja) 選択的スプライシングのアプタマー媒介性調節による遺伝子発現の調節
AU2020270960B2 (en) Engineered producer cell lines and methods of making and using the same
TW202329988A (zh) 調節cftr之組合物及方法
CN113710693B (zh) Dna结合结构域反式激活因子及其用途
CA3094217A1 (en) Gene therapeutics for treating bone disorders
US11077208B2 (en) Wilson's disease gene therapy
JP2025126223A (ja) 変形性関節症の治療方法
CN113913463B (zh) 抑制sost基因表达的重组质粒及其骨靶向重组腺相关病毒与应用
US20230272433A1 (en) Enhancing Utrophin Expression in Cell by Inducing Mutations Within Utrophin Regulatory Elements and Therapeutic Use Thereof
US20230265427A1 (en) Treatment of Genetic Dilated Cardiomyopathies
WO2009071679A1 (en) Novel aav vector and uses thereof
Li Optimization of Adeno-associated Virus Vectors Encoding Immune Checkpoint Protein for Arthritis Gene Therapy
WO2025259575A1 (en) Methods and compositions for treatment of duchenne muscular dystrophy
WO2024220758A9 (en) Rnas targeting activin a subunits

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination